share_log

Veru Shares Are Trading Higher Following Publication of Briefing Documents Ahead of the Nov. 9 FDA Adcom Meeting for Its COVID-19 Treatment Candidate.

Veru Shares Are Trading Higher Following Publication of Briefing Documents Ahead of the Nov. 9 FDA Adcom Meeting for Its COVID-19 Treatment Candidate.

在11月9日FDA Adcom會議之前發佈簡報文件後,Veru的股價上漲,VERU的候選新冠肺炎治療方案。
Benzinga ·  2022/11/07 10:31

Veru shares are trading higher following publication of briefing documents ahead of the Nov. 9 FDA Adcom meeting for its COVID-19 treatment candidate.

在11月9日FDA為其新冠肺炎候選藥物舉行的Adcom會議之前,Veru的股價在簡報文件公佈後走高。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論